Next Article in Journal
CD137 Enhancement of HPV Positive Head and Neck Squamous Cell Carcinoma Tumor Clearance
Previous Article in Journal
A Systematic Review of Recent Advances in Equine Influenza Vaccination
Previous Article in Special Issue
Schistosome Vaccine Adjuvants in Preclinical and Clinical Research
Article Menu

Export Article

Open AccessReview
Vaccines 2014, 2(4), 832-840; doi:10.3390/vaccines2040832

Peptide Vaccines for Hypertension and Diabetes Mellitus

1
Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Chiba University, Fukui University, 2-1 Yamada-oka, Suita, Osaka 565-0871, Japan
2
Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
*
Author to whom correspondence should be addressed.
Received: 8 May 2014 / Revised: 10 October 2014 / Accepted: 3 November 2014 / Published: 26 November 2014
(This article belongs to the Special Issue Peptide Vaccine)
View Full-Text   |   Download PDF [260 KB, uploaded 26 November 2014]   |  

Abstract

Vaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer’s disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets are usually specific antigens in cancer cells, allowing activated cytotoxic T cells (CTLs) to attach and remove the antigen-presenting cancer cells. In our therapeutic vaccines against hypertension, the target is angiotensin II (Ang II) and induced anti-Ang II antibodies could efficiently ameliorate high blood pressure. Similarly, we developed the therapeutic vaccine against DPP4 for diabetes mellitus. However, because Ang II or DPP4 is an endogenous hormone, we must avoid autoimmune disease induced by these vaccines. Therefore, our system was used to design a therapeutic vaccine that elicits anti-Ang II or DPP4 antibodies without CTL activation against Ang II or DPP4. In this review, we will describe our concept of therapeutic vaccines for hypertension and diabetes mellitus. View Full-Text
Keywords: vaccine; angiotensin II; DPP4 vaccine; angiotensin II; DPP4
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nakagami, H.; Koriyama, H.; Morishita, R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines 2014, 2, 832-840.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top